Analysis of Investigational Drugs in Biological Fluids - Method Development and Routine Assay
Abstract
Analytical methodologies were under development for the determination of the concentrations of the anti leishmanial compound, WR 6026 in blood and plasma; the radioprotective drugs WR 2721 and WR 3689 in plasma; the antimalarial compound WR 238,605 in blood and plasma; the anti malarial drug, mefloquine in plasma; the anti viral drug, ribavirin, and WR 249,992 in plasma; the anti malaial drug, beta not equal to arteether, and dihydroginghaosu in biological fluids, the anti malarial drug, halofantrine, and its metabolite, WR 178,460, in blood and plasma; the 4-hydroxymethyl and mono desethyl metabolites of WR 6026 (WR 254,421 and WR 211,789) in biological fluids; and the carboxyl metabolite of mefloquine, WR 160,972, in plasma. A study report was submitted for the WR 238,605 method. Routine assays for eight studies were underway during the fourth year of the contract for WR 6026 in human blood; WR 238,605 in beagle dog plasma and blood; pyridostigmine in human plasma; physostigmine in rat plasma, bile and tube bindings; and halofantrine in human plasma and blood.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 15, 1990
- Accession Number
- ADA227801
Entities
People
- Emil T. Lin
- Leslie Z. Benet
- Robert A. Upton
- Winnie L. Gee
Organizations
- University of California, San Francisco